Novartis drug shows promise in treating Fragile X syndrome

04/29/2010 | New York Times (tiered subscription model), The

An experimental drug from Novartis caused substantial improvement in behavior in a small study involving adults with Fragile X syndrome, a genetic condition linked to mental disorders such as autism. Dr. Mark C. Fishman, president of the Novartis Institutes for BioMedical Research, said researchers feel "pretty good about the data" but thinks that more clinical trials are necessary to prove effectiveness of the treatment.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC